首页> 外文期刊>Japanese Journal of Pharmacology >Hypocholesterolemic Action and Prevention of Cholesterol Absorption via the Gut by F-1394, a Potent Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitor, in Cholesterol Diet-Fed Rats
【24h】

Hypocholesterolemic Action and Prevention of Cholesterol Absorption via the Gut by F-1394, a Potent Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitor, in Cholesterol Diet-Fed Rats

机译:在胆固醇饮食喂养的大鼠中,F-1394是一种有效的酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制剂,可通过胆量降低胆固醇水平并防止胆固醇吸收。

获取原文
           

摘要

References(28) Cited-By(6) In the present study, we investigated the hypocholesterolemic effect of F-1394 ((ls, 2s)-2-[3-(2, 2-dimethylpropyl)-3-nonylureido]aminocyclohexane-1-yl 3-[N-(2, 2, 5, 5-tetramethyl-1, 3-dioxane-4-carbonyl)amino]propionate), a potent and selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), and the effect on cholesterol absorption via the gut in rats fed a 1 % cholesterol diet. Single administration of F-1394 to the cholesterol diet-fed rats at the doses of 3-30 mg/kg, p.o. decreased the serum cholesterol levels by 16 - 54% 3 hr after the administration. The ACAT activity in the small intestinal mucosa of the rats given orally F-1394 (30 mg/kg) was significantly inhibited 3 hr after the administration. The hypocholesterolemic action of F-1394 had a faster onset than that of DL-melinamide or CL-277, 082. The study by the dual isotope ratio method showed that F-1394 (30 mg/kg, p.o.) significantly suppressed the dietary cholesterol absorption. Furthermore, in the determination of cholesterol absorption by using 14C-cholesterol as the oral tracer, the administration of F-1394 (30 mg/kg, p.o.) 1 or 2 hr before or immediately after the application of the oral tracer significantly prevented the appearance of the radioactivity in the circulation by around 90%. These results indicate that oral administration of F-1394 inhibits the ACAT activity in the small intestinal mucosa and subsequently contributes much to the prevention of cholesterol absorption via the gut, resulting in the decrease in serum cholesterol levels in the cholesterol diet-fed rats. Furthermore, the effect of F-1394 appears immediately after its administration in contrast to that of DL-melinamide or CL-277, 082.
机译:参考文献(28)被引用的By(6)在本研究中,我们研究了F-1394((ls,2s)-2- [3-(2,2-二甲基丙基)-3-壬基脲基]氨基环己烷- 1-yl 3- [N-(2,2,5,5-tetramethyl-1,3-dioxane-4-羰基)氨基]丙酸酯),一种酰基辅酶A:胆固醇酰基转移酶(ACAT)的强效选择性抑制剂,以及饲喂1%胆固醇饮食的大鼠通过肠道对胆固醇吸收的影响。以3-30 mg / kg的剂量向胆固醇饮食喂养的大鼠单次施用F-1394,口服。服用3小时后,血清胆固醇水平降低了16-54%。口服F-1394(30 mg / kg)后3小时,大鼠小肠黏膜中的ACAT活性被显着抑制。 F-1394的降胆固醇作用起效快于DL-三聚氰胺或CL-277,082。双同位素比法研究表明,F-1394(30 mg / kg,口服)可显着抑制饮食中的胆固醇吸收。此外,在通过使用14C-胆固醇作为口服示踪剂测定胆固醇吸收的过程中,在施用口服示踪剂之前或之后1或2小时施用F-1394(30 mg / kg,口服)可显着防止外观循环中放射性的约90%。这些结果表明,口服F-1394抑制了小肠粘膜中的ACAT活性,并且随后对通过肠道吸收胆固醇起了很大作用,从而导致胆固醇饮食喂养的大鼠血清胆固醇水平降低。此外,与DL-蜜胺或CL-277,082相比,F-1394的作用在给药后立即显现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号